GBGB2008598.1A
GB202008598D0
(en)
|
2020-06-08 |
2020-06-08 |
Novel compounds
|
PCT/EP2021/065112
WO2021249909A1
(en)
|
2020-06-08 |
2021-06-07 |
1-(5-(2-cyanopyridin-4-yl)oxazole-2-carbonyl)-4-methylhexahydropyrrolo[3,4-b]pyr role-5(1h)-carbonitrile as usp30 inhibitor for use in the treatment of mitochondrial dysfunction, cancer and fibrosis
|
CA3186148A
CA3186148A1
(en)
|
2020-06-08 |
2021-06-07 |
1-(5-(2-cyanopyridin-4-yl)oxazole-2-carbonyl)-4-methylhexahydropyrrolo[3,4-b]pyr role-5(1h)-carbonitrile as usp30 inhibitor for use in the treatment of mitochondrial dysfunction, cancer and fibrosis
|
JP2022575399A
JP2023528087A
(en)
|
2020-06-08 |
2021-06-07 |
1-(5-(2-cyanopyridin-4-yl)oxazole-2-carbonyl)-4-methylhexahydropyrrolo[3] as USP30 inhibitors used in the treatment of mitochondrial dysfunction, cancer, and fibrosis ,4-b]pyrrole-5(1H)-carbonitrile
|
EP21732212.2A
EP4161929A1
(en)
|
2020-06-08 |
2021-06-07 |
1-(5-(2-cyanopyridin-4-yl)oxazole-2-carbonyl)-4-methylhexahydropyrrolo[3,4-b]pyr role-5(1h)-carbonitrile as usp30 inhibitor for use in the treatment of mitochondrial dysfunction, cancer and fibrosis
|
AU2021286831A
AU2021286831A1
(en)
|
2020-06-08 |
2021-06-07 |
1-(5-(2-cyanopyridin-4-yl)oxazole-2-carbonyl)-4- methylhexahydropyrrolo[3,4-b]pyrrole-5(1H)-carbonitrile as USP30 inhibitor for use in the treatment of mitochondrial dysfunction, cancer and fibrosis
|
MX2022015608A
MX2022015608A
(en)
|
2020-06-08 |
2021-06-07 |
1-(5-(2-cyanopyridin-4-yl)oxazole-2-carbonyl)-4-methylhexahydrop yrrolo[3,4-b]pyr role-5(1h)-carbonitrile as usp30 inhibitor for use in the treatment of mitochondrial dysfunction, cancer and fibrosis.
|
US18/008,352
US20230312580A1
(en)
|
2020-06-08 |
2021-06-07 |
1-(5-(2-cyanopyridin-4-yl)oxazole-2-carbonyl)-4-methylhexahydropyrrolo[3,4-b]pyr role-5(1h)-carbonitrile as usp30 inhibitor for use in the treatment of mitochondrial dysfunction, cancer and fibrosis
|
KR1020237000509A
KR20230022215A
(en)
|
2020-06-08 |
2021-06-07 |
1-(5-(2-cyanopyridin-4-yl)oxazole-2-carbonyl)-4-methylhexahydropyrrolo[3 as an inhibitor of USP30 for use in the treatment of mitochondrial dysfunction, cancer and fibrosis ,4-b] pyrrole-5 (1H) -carbonitrile
|
BR112022024794A
BR112022024794A2
(en)
|
2020-06-08 |
2021-06-07 |
HEXAHYDROPYROLO[3,4-B]PYROLE-5(1H)-CARBONITRILS WITH ACTIVITY AS USP30 INHIBITORS FOR USE IN THE TREATMENT OF MITOCHONDRIAL DYSFUNCTION, CANCER AND FIBROSIS
|
CN202180040683.1A
CN115836073A
(en)
|
2020-06-08 |
2021-06-07 |
1- (5- (2-cyanopyridin-4-yl) oxazole-2-carbonyl) -4-methylhexahydropyrrolo [3,4-B ] pyrrole-5 (1H) -carbonitrile as a USP30 inhibitor for the treatment of mitochondrial dysfunction, cancer and fibrosis
|
IL298785A
IL298785A
(en)
|
2020-06-08 |
2021-06-07 |
1-(5-(2-cyanopyridin-4-yl)oxazole-2-carbonyl)-4-methylhexahydropyrrolo[3,4-b]pyr role-5(1h)-carbonitrile as usp30 inhibitor for use in the treatment of mitochondrial dysfunction, cancer and fibrosis
|
CONC2022/0017233A
CO2022017233A2
(en)
|
2020-06-08 |
2022-11-30 |
1-(5-(2-cyanopyridin-4-yl)oxazol-2-carbonyl)-4-methylhexahydropyrrolo[3,4-b]pyrrole-5(1h)-carbonitrile as a usp30 inhibitor for use in the treatment of mitochondrial dysfunction, cancer and fibrosis
|